Dup15q Syndrome - Pipeline Insight, 2025

DelveInsight’s, Dup15q syndrome - Pipeline Insight, 2025,” report provides comprehensive insights about 4+ companies and 5+ pipeline drugs in Dup15q syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Dup15q syndrome Understanding

15q duplication syndrome (maternal dup15q) is characterized by hypotonia and motor delays, intellectual disability, autism spectrum disorder (ASD), and epilepsy including infantile spasms. Rarely, maternal dup15q may also be associated with psychosis or sudden unexplained death. Those with a maternal isodicentric 15q11.2-q13.1 supernumerary chromosome are typically more severely affected than those with an interstitial duplication. The diagnosis of maternal dup15q is established by detection of at least one extra maternally derived copy of the Prader-Willi/Angelman critical region, a region approximately 5 Mb long within chromosome region 15q11.2-q13.1. The extra copy or copies most commonly arise by one of two mechanisms:

• A maternal isodicentric 15q11.2-q13.1 supernumerary chromosome - idic(15) - typically comprising two extra copies of 15q11.2-q13.1 and resulting in tetrasomy for 15q11.2-q13.1 (~60-80%);
• A maternal interstitial 15q11.2-q13.1 duplication that typically includes one extra copy of 15q11.2-q13.1 within chromosome 15, resulting in trisomy for 15q11.2-q13.1 (~20-40%).TT

'Dup15q syndrome - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dup15q syndrome pipeline landscape is provided which includes the disease overview and Dup15q syndrome treatment guidelines. The assessment part of the report embraces, in depth Dup15q syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dup15q syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence R&D Dup15q syndrome. The therapies under development are focused on novel approaches to treat/improve Dup15q syndrome.

Dup15q syndrome Emerging Drugs

RAD011: Radius Health

Investigational drug RAD011 is a pharmaceutical-grade synthetic cannabidiol oral solution, manufactured utilizing traditional pharmaceutical manufacturing processes. The product has purity specifications that meet standardized regulatory and quality control requirements and, compared to the process of developing a plant-derived product, the synthetic manufacturing process usually enables increased consistency and greater precision in the product supply. RAD011 has been assessed in over 125 patients across multiple indications and has potential utilization in multiple neuro-endocrine, neurodevelopmental, or neuropsychiatric disease areas. Radius plans to study RAD011 in patients with Angelman syndrome, Prader-Willi syndrome, and infantile spasms.

Dup15q syndrome: Therapeutic Assessment

This segment of the report provides insights about the Dup15q syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Dup15q syndrome

There are approx. 4+ key companies which are developing the therapies Dup15q syndrome. The companies which have their Dup15q syndrome drug candidates in the most advanced stage, i.e Phase III include Radius Health

Phases

The report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Dup15q syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dup15q syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dup15q syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dup15q syndrome drugs.

Dup15q syndrome Report Insights

• Dup15q syndrome Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Dup15q syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Dup15q syndrome drugs?
• How many Dup15q syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dup15q syndrome?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dup15q syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dup15q syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Q-State Biosciences
• Ovid Therapeutics
• Radius Health
• Zogenix

Key Products

• Dup15q Research Project
• Soticlestat
• RAD011
• ZX008